CORDIS
EU research results

CORDIS

English EN

Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification - Sofia ref.: 115881

Objective

The stated goal of RHAPSODY is to define a molecular taxonomy of type 2 diabetes mellitus (T2D) that will support patient segmentation, inform clinical trial design, and the establishment of regulatory paths for the adoption of novel strategies for diabetes prevention and treatment. To address these goals, RHAPSODY will bring together prominent European experts, including the leaders of the diabetes-relevant IMI1 projects to identify, validate and characterize causal biomarkers for T2D subtypes and progression. Our plans are built upon: (a) access to large European cohorts with comprehensive genetic analyses and rich longitudinal clinical and biochemical data and samples; (b) detailed multi-omic maps of key T2D-relevant tissues and organs; (c) large expertise in the development and use of novel genetic, epigenetic, biochemical and physiological experimental approaches; (d) the ability to combine existing and novel data sets through effective data federation and use of these datasets in systems biology approaches towards precision medicine; and (e) expertise in regulatory approval, health economics and patient engagement. These activities will lead to the discovery of novel biomarkers for improved T2D taxonomy, to support development of pharmaceutical activities, and for use in precision medicine to improve health in Europe and worldwide.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITE DE LAUSANNE

Address

Quartier Unil-Centre BÂTiment Unicentre
1015 Lausanne

Switzerland

Activity type

Higher or Secondary Education Establishments

Participants (26)

Sort alphabetically

Sort by EU Contribution

Expand all

LUNDS UNIVERSITET

Sweden

EU Contribution

€ 1 071 853

TECHNISCHE UNIVERSITAET DRESDEN

Germany

EU Contribution

€ 518 723

UNIVERSITA DI PISA

Italy

EU Contribution

€ 389 043

UNIVERSITE PARIS DIDEROT - PARIS 7

France

EU Contribution

€ 418 970

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 408 745

UNIVERSITE LIBRE DE BRUXELLES

Belgium

EU Contribution

€ 398 395

SIB INSTITUT SUISSE DE BIOINFORMATIQUE

Switzerland

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

EU Contribution

€ 748 130

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

France

EU Contribution

€ 468 923

ITA-SUOMEN YLIOPISTO

Finland

EU Contribution

€ 472 587

UNIVERSITY OF DUNDEE

United Kingdom

EU Contribution

€ 499 121

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom

EU Contribution

€ 518 741

EBERHARD KARLS UNIVERSITAET TUEBINGEN

Germany

EU Contribution

€ 389 966

LIPOTYPE

Germany

EU Contribution

€ 418 968

KOBENHAVNS UNIVERSITET

Denmark

EU Contribution

€ 599 151

AZIENDA OSPEDALIERA CITTA DELLA SALUTE E DELLA SCIENZA DI TORINO

Italy

EU Contribution

€ 104 743

ACADEMISCH ZIEKENHUIS GRONINGEN

Netherlands

EU Contribution

€ 105 380

CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE

France

EU Contribution

€ 299 296

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

EU Contribution

€ 149 632

SCIPROM SARL

Switzerland

INSTITUT DE RECHERCHES SERVIER

France

JANSSEN PHARMACEUTICA NV

Belgium

NOVO NORDISK A/S

Denmark

SANOFI-AVENTIS DEUTSCHLAND GMBH

Germany

STICHTING VUMC

Netherlands

EU Contribution

€ 149 633

Eli Lilly and Company Limited

United Kingdom

Project information

Grant agreement ID: 115881

Status

Ongoing project

  • Start date

    1 April 2016

  • End date

    31 March 2020

Funded under:

H2020-EU.3.1.7.6.

  • Overall budget:

    € 18 488 749

  • EU contribution

    € 8 130 000

Coordinated by:

UNIVERSITE DE LAUSANNE

Switzerland